Newsfeeds - Spark Newswire

2 minute read

Viracta Therapeutics Announces Orphan Drug Designation Granted By FDA For Its All-Oral Combination Of Nanatinostat And Valganciclovir For The Treatment Of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma

Today, 3:45 AM

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted its all-oral combination

VIRX

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 3:45 AM

Gainers Dermata Therapeutics (NASDAQ:DRMA) stock increased by 28.63% to $5.66 during Monday's after-market session. The market value of their outstanding shares is at $47.1 million.

CALA

2 minute read

FDA
News

Viracta Therapeutics Initiates Phase 1b/2 Trial In Epstein-Barr Virus-Positive (EBV+) Solid Tumors

By Benzinga Newsdesk

Today, 3:45 AM

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of a multinational Phase 1b/2 trial in patients with

VIRX

2 minute read

Viracta Therapeutics Reacquires Exclusive Development And Commercialization Rights For All-Oral Combination Therapy In China For $4M

By Benzinga Newsdesk

Today, 3:45 AM

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has reacquired the exclusive rights to develop and commercialize its

VIRX

1 minute read

FDA
News

Viracta Therapeutics-Sponsored Study Titled ‘An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)’ Posted To ClinicalTrials.Gov

By Benzinga Newsdesk

Today, 3:45 AM

https://clinicaltrials.gov/ct2/show/NCT05011058

VIRX

1 minute read

Viracta Therapeutics Q2 EPS $(0.25) Up From $(15.52) YoY

By Benzinga Newsdesk

Today, 3:45 AM

Viracta Therapeutics (NASDAQ:VIRX) reported quarterly losses of $(0.25) per share. This is a 98.39 percent increase over losses of $(15.52) per share from the same period last year.

VIRX

2 minute read

FDA
News

Viracta Therapeutics Announces FDA Clearance Of IND Application For Phase 1b/2 Trial In Epstein-Barr Virus-Positive Solid Tumors

By Benzinga Newsdesk

Today, 3:45 AM

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Food and Drug Administration (FDA) has cleared

VIRX

5 minute read

Uncategorized

77 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:45 AM

Gainers AMC Entertainment Holdings, Inc. (NYSE: AMC) shares surged 23.7% to close at $12.77. Moxian, Inc. (NASDAQ: MOXC) jumped 23.6% to close at $9.52.

AHPI